Citigroup Maintains Mirati Therapeutics to Buy with Price Target $23.00

Brokerage firm Citigroup Maintains its rating on Mirati Therapeutics(NASDAQ:MRTX). In a research note issued to the investors, the brokerage major Lowers the price-target to $23.00 per share. The shares have been rated Buy. The rating by Citigroup was issued on Jun 6, 2016.

In a different note, On May 6, 2016, Avondale Partners said it Upgrades its rating on Mirati Therapeutics. In the research note, the firm Lowers the price-target to $22.00 per share. The shares have been rated ‘Market Outperform’ by the firm. On Mar 10, 2016, Jefferies said it Maintains its rating on Mirati Therapeutics. In the research note, the firm Lowers the price-target to $33.00 per share. The shares have been rated ‘Buy’ by the firm. On Mar 10, 2016, Leerink Swann said it Maintains its rating on Mirati Therapeutics. In the research note, the firm Lowers the price-target to $50.00 per share. The shares have been rated ‘Outperform’ by the firm.

Mirati Therapeutics (MRTX) shares turned negative on Fridays trading session with the shares closing down -1.53 points or -15.90% at a volume of 12,07,149. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $9.41. The peak price level was also seen at $9.41 while the days lowest was $8.09. Finally the shares closed at $8.09. The 52-week high of the shares is $52 while the 52-week low is $8.09. According to the latest information available, the market cap of the company is $161 M.

Mirati Therapeutics(MRTX) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-1.13. Analysts had estimated an EPS of $-0.99.

Several Insider Transactions has been reported to the SEC. On May 9, 2016, Ltd. Braslyn (10% owner) purchased 65,782 shares at $17.72 per share price.Also, On Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price.On May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price, according to the Form-4 filing with the securities and exchange commission.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *